Literature DB >> 25970831

Nuclear Akt: target for breast cancer therapy?

Britta Merz1, Peter Nader Malak, Oliver Rothfuss.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25970831      PMCID： PMC5242241          DOI： 10.1080/15384101.2015.1049089

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  4 in total

1.  Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes.

Authors:  Isao Shiraishi; Jaime Melendez; Youngkeun Ahn; Maryanne Skavdahl; Elizabeth Murphy; Sara Welch; Erik Schaefer; Kenneth Walsh; Anthony Rosenzweig; Daniele Torella; Daria Nurzynska; Jan Kajstura; Annarosa Leri; Piero Anversa; Mark A Sussman
Journal:  Circ Res       Date:  2004-02-26       Impact factor: 17.367

2.  Cancer stem cell-like phenotype and survival are coordinately regulated by Akt/FoxO/Bim pathway.

Authors:  Ricardo Gargini; Juan P Cerliani; Maribel Escoll; Inés M Antón; Francisco Wandosell
Journal:  Stem Cells       Date:  2015-03       Impact factor: 6.277

Review 3.  Understanding cancer stem cell heterogeneity and plasticity.

Authors:  Dean G Tang
Journal:  Cell Res       Date:  2012-01-17       Impact factor: 25.617

4.  Unscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin's anticancer toxicity.

Authors:  Subbareddy Maddika; Soumya Panigrahi; Emilia Wiechec; Sebastian Wesselborg; Ute Fischer; Klaus Schulze-Osthoff; Marek Los
Journal:  Mol Cell Biol       Date:  2008-12-22       Impact factor: 4.272
  4 in total
  1 in total

1.  Novel AKT phosphorylation sites identified in the pluripotency factors OCT4, SOX2 and KLF4.

Authors:  Peter N Malak; Benjamin Dannenmann; Alexander Hirth; Oliver C Rothfuss; Klaus Schulze-Osthoff
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.